Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM

Unity Health Toronto

Status and phase: Completed; Phase 2

Conditions: Coronary Heart Disease; Type2 Diabetes

Treatments: Dietary Supplement: wheat bran; Dietary Supplement: konjac glucomannan

Study type: Interventional

Funder types: Other

Identifiers

NCT03741660

Konjac in T2DM

Details and patient eligibility

About

To examine whether Konjac-mannan fiber improves metabolic control measured by glycemia, lipidemia, and blood pressure in individuals with type-2 diabetes.

Enrollment: 11 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hyperlipidemia controlled by medication
• hypertension controlled by medication
• type 2 diabetes controlled by medication
• minimum 3 years since onset of all three conditions
• sedentary lifestyle

Exclusion criteria

• regular smoking
• regular alcohol consumption
• family history of premature coronary heart disease
• hypothyroidism
• renal, hepatic or gastrointestinal disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

11 participants in 2 patient groups, including a placebo group

Konjac-mannan

Experimental group

Description:

Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet

Treatment:

Dietary Supplement: konjac glucomannan

Placebo

Placebo Comparator group

Description:

wheat bran fiber biscuits with NCEP Step II metabolically controlled diet

Treatment:

Dietary Supplement: wheat bran